Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HPV vaccine study in women living with HIV
PACTR202501900693468Phase 3Not yet recruiting
- Sponsor
- Serum Institute of India
- Start
- Jun 2024
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
Phase 3 trial of CERVAVAC and qHPV vaccine in human papillomavirus infection (2 arms), sponsored by Serum Institute of India. Primary endpoint: Geometric mean titers of anti-HPV 16 and 18 IgG antibodies. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
CERVAVACqHPV vaccine
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on PACTR202501900693468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202501900693468.